144 related articles for article (PubMed ID: 34298376)
1. Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcomas.
Kantidakis G; Litière S; Neven A; Vinches M; Judson I; Schöffski P; Wardelmann E; Stacchiotti S; D'Ambrosio L; Marréaud S; van der Graaf WTA; Kasper B; Fiocco M; Gelderblom H
Eur J Cancer; 2021 Sep; 154():253-268. PubMed ID: 34298376
[TBL] [Abstract][Full Text] [Related]
2. New benchmarks to design clinical trials with advanced or metastatic liposarcoma or synovial sarcoma patients: An EORTC - Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis based on a literature review for soft-tissue sarcomas.
Kantidakis G; Litière S; Neven A; Vinches M; Judson I; Blay JY; Wardelmann E; Stacchiotti S; D'Ambrosio L; Marréaud S; van der Graaf WTA; Kasper B; Fiocco M; Gelderblom H
Eur J Cancer; 2022 Oct; 174():261-276. PubMed ID: 36116829
[TBL] [Abstract][Full Text] [Related]
3. Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072.
Benson C; Ray-Coquard I; Sleijfer S; Litière S; Blay JY; Le Cesne A; Papai Z; Judson I; Schöffski P; Chawla S; Gil T; Piperno-Neumann S; Marréaud S; Dewji MR; van der Graaf WTA
Gynecol Oncol; 2016 Jul; 142(1):89-94. PubMed ID: 27012429
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
D'Ambrosio L; Touati N; Blay JY; Grignani G; Flippot R; Czarnecka AM; Piperno-Neumann S; Martin-Broto J; Sanfilippo R; Katz D; Duffaud F; Vincenzi B; Stark DP; Mazzeo F; Tuchscherer A; Chevreau C; Sherriff J; Estival A; Litière S; Sents W; Ray-Coquard I; Tolomeo F; Le Cesne A; Rutkowski P; Stacchiotti S; Kasper B; Gelderblom H; Gronchi A;
Cancer; 2020 Jun; 126(11):2637-2647. PubMed ID: 32129883
[TBL] [Abstract][Full Text] [Related]
5. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.
Pautier P; Floquet A; Chevreau C; Penel N; Guillemet C; Delcambre C; Cupissol D; Selle F; Isambert N; Piperno-Neumann S; Thyss A; Bertucci F; Bompas E; Alexandre J; Collard O; Lavau-Denes S; Soulié P; Toulmonde M; Le Cesne A; Lacas B; Duffaud F;
Lancet Oncol; 2015 Apr; 16(4):457-64. PubMed ID: 25795402
[TBL] [Abstract][Full Text] [Related]
6. Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy.
Ray-Coquard I; Rizzo E; Blay JY; Casali P; Judson I; Hansen AK; Lindner LH; Dei Tos AP; Gelderblom H; Marreaud S; Litière S; Rutkowski P; Hohenberger P; Gronchi A; van der Graaf WT
Gynecol Oncol; 2016 Jul; 142(1):95-101. PubMed ID: 27208537
[TBL] [Abstract][Full Text] [Related]
7. "Low-grade leiomyosarcoma" and late-recurring smooth muscle tumors of the uterus: a heterogenous collection of frequently misdiagnosed tumors associated with an overall favorable prognosis relative to conventional uterine leiomyosarcomas.
Veras E; Zivanovic O; Jacks L; Chiappetta D; Hensley M; Soslow R
Am J Surg Pathol; 2011 Nov; 35(11):1626-37. PubMed ID: 21921786
[TBL] [Abstract][Full Text] [Related]
8. Comparison of current staging systems and a novel staging system for uterine leiomyosarcoma.
Giuntoli RL; Lessard-Anderson CR; Gerardi MA; Kushnir CL; Cliby WA; Metzinger DS; Gostout BS
Int J Gynecol Cancer; 2013 Jun; 23(5):869-76. PubMed ID: 23669444
[TBL] [Abstract][Full Text] [Related]
9. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
[TBL] [Abstract][Full Text] [Related]
10. Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: an individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validation.
Hasan B; Greillier L; Pallis A; Menis J; Gaafar R; Sylvester R; Fennell DA; Baas P; Surmont V; Van Meerbeeck JP; O'brien ME
Eur J Cancer; 2014 Nov; 50(16):2771-82. PubMed ID: 25155251
[TBL] [Abstract][Full Text] [Related]
11. Eribulin in Patients with Liposarcoma and Leiomyosarcoma: A Retrospective Single-Center Experience.
Steinbrecher O; Brodowicz T; Raderer M; Scharrer A; Fabsits J; Lamm W
Oncology; 2023; 101(2):89-95. PubMed ID: 36273457
[TBL] [Abstract][Full Text] [Related]
12. Soft Tissue and Uterine Leiomyosarcoma.
George S; Serrano C; Hensley ML; Ray-Coquard I
J Clin Oncol; 2018 Jan; 36(2):144-150. PubMed ID: 29220301
[TBL] [Abstract][Full Text] [Related]
13. Management of advanced uterine leiomyosarcoma.
Hyman DM; Grisham RN; Hensley ML
Curr Opin Oncol; 2014 Jul; 26(4):422-7. PubMed ID: 24840518
[TBL] [Abstract][Full Text] [Related]
14. Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years.
Penel N; Van Glabbeke M; Marreaud S; Ouali M; Blay JY; Hohenberger P
Ann Oncol; 2011 Jun; 22(6):1266-1272. PubMed ID: 21183581
[TBL] [Abstract][Full Text] [Related]
15. Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience.
Wang Z; Shi N; Naing A; Janku F; Subbiah V; Araujo DM; Patel SR; Ludwig JA; Ramondetta LM; Levenback CF; Ramirez PT; Piha-Paul SA; Hong D; Karp DD; Tsimberidou AM; Meric-Bernstam F; Fu S
Cancer Med; 2016 Dec; 5(12):3437-3444. PubMed ID: 27882721
[TBL] [Abstract][Full Text] [Related]
16. Uterine leiomyosarcoma and endometrial stromal sarcoma have unique miRNA signatures.
Ravid Y; Formanski M; Smith Y; Reich R; Davidson B
Gynecol Oncol; 2016 Mar; 140(3):512-7. PubMed ID: 26768834
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis.
Saerens M; Brusselaers N; Rottey S; Decruyenaere A; Creytens D; Lapeire L
Eur J Cancer; 2021 Jul; 152():165-182. PubMed ID: 34107450
[TBL] [Abstract][Full Text] [Related]
18. Metastatic uterine leiomyosarcomas: a single-institution experience.
Bernstein-Molho R; Grisaro D; Soyfer V; Safra T; Merimsky O
Int J Gynecol Cancer; 2010 Feb; 20(2):255-60. PubMed ID: 20134269
[TBL] [Abstract][Full Text] [Related]
19. Outcome and prognosis in uterine sarcoma and malignant mixed Mullerian tumor.
Burghaus S; Halmen S; Gass P; Mehlhorn G; Schrauder MG; Lux MP; Renner SP; Beckmann MW; Hein A; Thiel FC
Arch Gynecol Obstet; 2016 Aug; 294(2):343-51. PubMed ID: 26711836
[TBL] [Abstract][Full Text] [Related]
20. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874).
Reed NS; Mangioni C; Malmström H; Scarfone G; Poveda A; Pecorelli S; Tateo S; Franchi M; Jobsen JJ; Coens C; Teodorovic I; Vergote I; Vermorken JB;
Eur J Cancer; 2008 Apr; 44(6):808-18. PubMed ID: 18378136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]